Ganglioside GM3 as a gatekeeper of obesity-associated insulin resistance: evidence and mechanisms

Christopher Lipina, Harinder S. Hundal (Lead / Corresponding author)

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Gangliosides constitute a large family of sialic acid-containing glycosphingolipids which play a key regulatory role in a diverse array of cellular processes, including receptor-associated signalling. Accordingly, the aberrant production of the ganglioside GM3 has been linked to pathophysiological changes associated with obesity, which in turn can lead to metabolic disorders such as insulin resistance and type 2 diabetes mellitus. This review examines the role of GM3 in mediating obesity-induced perturbations in metabolic function, including impaired insulin action. By doing so, we highlight the potential use of therapies targeting GM3 biosynthesis in order to counteract obesity-related metabolic disorders.

Original languageEnglish
Pages (from-to)3221-3227
Number of pages7
JournalFEBS Letters
Volume589
Issue number21
Early online date2 Oct 2015
DOIs
Publication statusPublished - 24 Oct 2015

Fingerprint

G(M3) Ganglioside
Insulin Resistance
Obesity
Insulin
Glycosphingolipids
Gangliosides
Biosynthesis
N-Acetylneuraminic Acid
Medical problems
Type 2 Diabetes Mellitus
Therapeutics

Cite this

@article{fdd9195cd1fa45cb9ead36dea070ec44,
title = "Ganglioside GM3 as a gatekeeper of obesity-associated insulin resistance: evidence and mechanisms",
abstract = "Gangliosides constitute a large family of sialic acid-containing glycosphingolipids which play a key regulatory role in a diverse array of cellular processes, including receptor-associated signalling. Accordingly, the aberrant production of the ganglioside GM3 has been linked to pathophysiological changes associated with obesity, which in turn can lead to metabolic disorders such as insulin resistance and type 2 diabetes mellitus. This review examines the role of GM3 in mediating obesity-induced perturbations in metabolic function, including impaired insulin action. By doing so, we highlight the potential use of therapies targeting GM3 biosynthesis in order to counteract obesity-related metabolic disorders.",
author = "Christopher Lipina and Hundal, {Harinder S.}",
note = "Copyright {\circledC} 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.",
year = "2015",
month = "10",
day = "24",
doi = "10.1016/j.febslet.2015.09.018",
language = "English",
volume = "589",
pages = "3221--3227",
journal = "FEBS Letters",
issn = "0014-5793",
publisher = "Wiley",
number = "21",

}

TY - JOUR

T1 - Ganglioside GM3 as a gatekeeper of obesity-associated insulin resistance

T2 - evidence and mechanisms

AU - Lipina, Christopher

AU - Hundal, Harinder S.

N1 - Copyright © 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

PY - 2015/10/24

Y1 - 2015/10/24

N2 - Gangliosides constitute a large family of sialic acid-containing glycosphingolipids which play a key regulatory role in a diverse array of cellular processes, including receptor-associated signalling. Accordingly, the aberrant production of the ganglioside GM3 has been linked to pathophysiological changes associated with obesity, which in turn can lead to metabolic disorders such as insulin resistance and type 2 diabetes mellitus. This review examines the role of GM3 in mediating obesity-induced perturbations in metabolic function, including impaired insulin action. By doing so, we highlight the potential use of therapies targeting GM3 biosynthesis in order to counteract obesity-related metabolic disorders.

AB - Gangliosides constitute a large family of sialic acid-containing glycosphingolipids which play a key regulatory role in a diverse array of cellular processes, including receptor-associated signalling. Accordingly, the aberrant production of the ganglioside GM3 has been linked to pathophysiological changes associated with obesity, which in turn can lead to metabolic disorders such as insulin resistance and type 2 diabetes mellitus. This review examines the role of GM3 in mediating obesity-induced perturbations in metabolic function, including impaired insulin action. By doing so, we highlight the potential use of therapies targeting GM3 biosynthesis in order to counteract obesity-related metabolic disorders.

U2 - 10.1016/j.febslet.2015.09.018

DO - 10.1016/j.febslet.2015.09.018

M3 - Article

C2 - 26434718

VL - 589

SP - 3221

EP - 3227

JO - FEBS Letters

JF - FEBS Letters

SN - 0014-5793

IS - 21

ER -